Lyon (France) and Cambridge (MA, US), 7 June 2024 - 5.45pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced the availability of preparatory documents for the Combined General Meeting of 28 June 2024.
Shareholders of PHAXIAM Therapeutics are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company's registered office at 60 avenue Rockefeller - 69008 Lyon (France).
Shareholders have the following options for attending the General Meeting:
- Attend the General Meeting in person;
- Vote remotely by post or over Internet on the secure Votaccess voting platform; or
- Give a proxy to any natural person or legal entity of their choice, in accordance with the applicable legal and regulatory conditions, or give a proxy to the Chairman of the General Meeting. The Chairman will then vote on their behalf in favor of adopting the draft resolutions presented or approved by the Board of Directors and against adopting all other draft resolutions.
Availability of the Documents relating to the General Meeting
The notice of meeting and convening notice, including the agenda and draft resolutions, as well as the main conditions for attending and voting at the Combined General Meeting, were published in the “Bulletin des Annonces Légales et Obligatoires” n°62 and n°69 on 22 May 2024 and 7 June 2024 respectively.
The preparatory documents and information relating to this General Meeting are made available to shareholders in accordance with legal and regulatory requirements, and are available on the website: https://phaxiam.com, section ‘Investors / General Meeting / 2024’. Shareholders are invited to consult this section regularly, as it may be updated to specify the definitive arrangements for attending this General Meeting in the light of legal and regulatory requirements.
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.phaxiam.com
Contacts
| PHAXIAM Eric Soyer COO & CFO +33 4 78 74 44 38 investors@phaxiam.com | NewCap Mathilde Bohin / Dušan Orešanský Investor Relations Arthur Rouillé Media Relations +33 1 44 71 94 94 phaxiam@newcap.eu |
Forward-looking information
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical programs, development plans, business and regulatory strategy and anticipated future performance of PHAXIAM and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond PHAXIAM's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Investor should carefully read the risk factors section of the Company which can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), including in the Company’s 2023 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 5, 2024 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. PHAXIAM disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in PHAXIAM’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Attachment
